Arvind Bothra, vice president of institutional research at Religare Capital Markets is positive on Aurobindo Pharma. "Its US business is continuing to do exceedingly well, both on execution of product launches as well as the quality of product approvals," he adds.
first published: Dec 20, 2013 06:00 pm
A collection of the most-viewed Moneycontrol videos.
Nifty Slips Below 26,100 Amid Sluggish Trade, Midcaps Struggle; IT Lends Support | Closing Bell Live
Live: Can Nifty reach its all-time high levels this week? | Opening Bell
This Tenant says Andheri West is better than SOBO | The tenant
Nifty Clocks Second Week Of Gains But Still Awaits New Peak;Midcaps Snap 7-Week Run|Closing Bell
